Future Directions of Compound Management Field Require Further Evolution of Drug Discovery Processes

IQPC’s 7th Annual Compound Management & Integrity Summit brings together Pharmaceutical Professionals, Clinical Research Organizations and Industry Experts to address evolving industry concerns
July 29, 2011 - PRLog -- PHILADELPHIA, PA  – Pharma IQ, a division of IQPC, announces the 7th Annual Compound Management & Integrity Summit (http://www.compoundmanagementsummit.com), taking place September 26 to 30, 2011 in Philadelphia.  Industry leaders taking part in the Summit offer perspectives on future directions of the compound management & integrity (CMI) field, case studies and best practices within the industry.

Drug discovery is increasingly complex and costs for developing a drug are increasing, so having a well organized, efficient and low-cost compound management strategy to continuously support the drug discovery pipeline is essential.  The role of Clinical Research Organizations (CROs) in the drug discovery process is ever-increasing and constantly evolving, and as data management and distribution efforts improve, there is increased opportunity for leveraging CROs within drug discovery research.

The 7th Compound Management & Integrity Summit investigates the internal function of compound management & integrity strategies currently used within the pharmaceutical and biotechnology industries, and examines future directions of the CMI field, using case study examples from industry leaders and benchmark best practices. Speakers from Pfizer, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Merck & Co., Inc., GlaxoSmithKline and more investigate topics that include:

•   Investigating outsourcing programs and opportunities while cutting costs and reducing bottlenecks
•   Benchmarking best practices for building a strategic sample management program
•   Implementing novel technologies and tools to boost automation
•   Laboratory automation through streamlining processes and increasing efficiency
•   Quality control and assessing key drivers for unifying a single compound management system

For more information on the Summit, please visit http://www.compoundmanagementsummit.com or contact Robert Littlefield, Program Director at Robert.Littlefield@iqpc.com.

Source:Ashley Rowe
Email:***@iqpc.com Email Verified
Tags:Compound Management, Drug Discovery, Pharmaceuticals, Drug Development, Clinical Research Organizations
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share